In particular, the overactivity of exportin 1 (XPO1/CRM1) in various cancers, such as ovarian carcinoma, glioma, and pancreatic cancer, highlights the need to target both NPC function and nuclear export processes in therapeutic strategies. Here, XPO1 is linked to pancreatic neoplasm.